Bio-Rad Laboratories, Inc.

BIO Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.

Revenue
+0.52%
EPS
+234.8%
Free cash flow
+8.07%
Total debt
+0.11%

Quarter to September 2026, against a year earlier

382.51 13.51 +3.66%
Market cap
$9.9B
P/E
10.0×
Fwd P/E
44.7×
Dividend yield
—
F-score
5/9
Altman Z
3.20
Beneish M
−2.29
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
6 5 7 5

+8 more TTM periods

ROE
14.27% 3.11% 2.50% 10.84%
ROA
9.99% 2.17% 1.75% 7.62%
ROIC
(0.54%) 0.49% 0.55% 0.41%
Return on Tangible Assets
39.11% 8.63% 6.61% 25.94%
Average Days of Receivables
59.49 62.28 60.07 65.08
Free Cash Flow per Share
12.29 13.20 13.26 13.74
Free Cash Flow
329.10 353.10 357.40 374.70
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026